Abstract: The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3).

Abstract: A sweat sensor device (200) includes one or more sweat sensors (220) and a seal (280) covering the one or more sweat sensors (220). The seal (280) is adapted to protect the sweat sensors (220) from outside contaminants when the device (200) is placed on the skin (12). The sweat sensor device (200) may include an absorbing medium (230) to absorb sweat from the skin (12) that is covered by the seal (280). The seal (280) can be permeable to gas, permeable to water and impermeable to at least one aqueous solute, or selectively permeable to at least one aqueous solute. The sweat sensor device (200) may include an artificial sweat stimulation mechanism (345) for stimulating sweat when the device (200) is placed on the skin (12).

Abstract: Disclosed are kits and methods for determining the presence or absence of an antibody of interest in a biological sample of a subject. In particular, the methods may detect either pathological or beneficial antibodies. The method may include the step of contacting a biological sample from a subject with a substrate conjugated to an antigen and an Fc receptor operatively linked to a detectable label. Detection of the label may indicate the presence or absence of an antibody of interest.

Abstract: Devices that sense sweat and are capable of providing chronological assurance are described. The device uses at least one sensor to measure sweat or its components and to determine a sweat sampling rate. The chronological assurance is determined, at least in part, using the sweat sampling rate. The sweat sampling rate may be determined, at least in part, using a sweat volume and/or a sweat generation rate, both of which may be measured or predetermined.

Abstract: A sensor for isolating, identifying, and quantifying one or more analytes in a sample is provided, the sensor having a metal substrate base and a polymer waveguide disposed on the metal substrate base, the polymer waveguide including an optical channel and a polymer disposed in the optical channel; wherein the polymer waveguide optically couples a first and a second fiber optic cable. Also provided herein are methods of using the sensor for isolating, identifying, and quantifying one or more analytes in a sample, the method including contacting the polymer waveguide with a sample, sequentially heating the sensor to a plurality of temperature thresholds, obtaining an optical output at each temperature threshold, and analyzing differences in sequentially-obtained optical outputs in order to identify and determine concentrations of individual analytes of interest in the sample.

Abstract: Methods of treating a psychiatric disorder in a subject are provided which include placing at least one anode on an area of the subject's back over the dorsal spinal cord at the level of one or more of: thoracic vertebra 7 (T7), 8 (T8), 9 (T9), 10 (T10), 11 (T11), and 12 (T12) and lumbar vertebra 1 (L1); placing at least one cathode on an area of the subject's back which is generally rostral with reference to the anode; connecting the anode and the cathode to at least one source of direct and/or alternating electrical current; delivering direct current to the anode for a treatment period of time, the treatment period of time defining a tsDCS and/or tsACS treatment session, thereby modulating spinal input to the brain of the subject, decreasing sympathetic activity and reducing one or more symptoms and/or comorbidities associated with the psychiatric disorder.

Abstract: Non-invasive electroencephalogram (EEG)-based methods for detecting a spreading depolarization secondary to a brain injury in a patient who exhibits high-amplitude delta activity in at least one channel of a scalp EEG of an injured brain hemisphere of the patient include (a) recording a baseline scalp EEG pattern in the patient at a channel exhibiting high amplitude delta activity; (b) recording a continuous scalp EEG pattern in the patient across a time frame at the at least one channel; and (c) detecting a spreading depolarization during the time frame by observing at least one feature indicative of a spreading depolarization in the continuous scalp EEG recording pattern relative to the baseline scalp EEG pattern at the at least one channel. Scalp EEG recordings are time-compressed prior to analysis. Methods of treating brain-injured patients and triaging brain-injured patients apply the non-invasive EEG methods.

Abstract: Systems and methods of use and fabrication are described for a non-volatile resistive random access memory (RRAM) multi-terminal device including a first electrode, a second electrode, a metal oxide disposed between the first electrode and the second electrode, and an at least first gate configured to apply a voltage bias to change a resistive state in the metal oxide.

Abstract: A vascular implant device configured to decrease turbulence in blood flow through an arteriovenous fistula is described. The implant includes an arterial section having a straight hollow tube, a venous section having a curved hollow tube divided into an orthogonal portion at the juncture of the arterial section, a curved portion, and a straight extension portion, and having a continual lumen and lumen surface. The curved portion curves approximately 90 degrees with respect to the arterial section, and the extension portion extends substantially parallel to the arterial section. A plurality of flow-conditioning tabs are located along the lumen surface in arrangements precisely designed to convert the turbulent blood flow that enters the venous section into substantially laminar flow, and to minimize oscillatory shear stress on the venous endothelium as the blood flow exits the device and enters the vein.

Abstract: A laminate which can serve as either a smart window or a smart mirror is formed using first and second substrates coated with transparent first and second electrodes which are separated by foraminous layer and a third grid-like linear electrode insulated from the first and second electrodes. The foraminous layer includes spacers defining a cell space which is filled with a colloidal ink having first and second particles. The first particles have a positive charge and a first color and second particles having a negative charge and a second color different from the first color. By altering the voltages of the first, second and third electrodes, one can achieve different light transmission characteristics which, for example, can alter the color temperature of the light transmitted through the laminate or enhance reflective colors.

Abstract: Methods for targeting adaptive responses to chemotherapy are described. In various embodiments, a method comprises administering at least one compound that inhibits S6K1, mTORC1 or upstream or downstream pathway components of S6K1 or mTORC1, in association with administration of at least one inhibitor of PPAR?, PPAR?, or PGC1?. In various embodiments, the compound that inhibits S6K1, mTORC1, or upstream or downstream pathway components of S6K1 or mTORC1 is rapamycin, everolimus, temsirolimus, or imatinib. The inhibitor of PPAR?, PPAR?, or PGC1? can be an antagonist or an inverse agonist selected from GW6471, GSK3787, GSK0660, and ST247.

Abstract: A sensor for isolating, identifying, and quantifying one or more analytes in a sample is provided. Also provided are methods of isolating, identifying, and quantifying one or more analytes in a sample, the method including contacting a polymer waveguide with a sample, sequentially heating the polymer waveguide to a plurality of temperature thresholds, obtaining an optical output at each temperature threshold, and analyzing differences in sequentially-obtained optical outputs in order to identify and determine concentrations of individual analytes of interest in the sample.

Abstract: Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. In particular, the invention relates to identifying one or more biomarkers associated with septic shock in pediatric patients, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of one or more of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.

Abstract: Computer-implemented methods and automated systems for real-time detection of spreading depolarizations in a brain injured patient, based an algorithm of (a) providing a reference data base of spreading depolarization waveform templates generated from EEG recordings of confirmed spreading depolarizations (SD) in a reference brain-injured patient cohort; (b) recording an EEG of the brain injured patient to generate recorded EEG waveforms; (c) detecting a slow potential change present in a recorded EEG waveform by applying a power spectral density estimate to the recorded waveform; (d) comparing a detected SPC to a reference database of SD waveform template to identify a candidate SD; and (e) rejecting a candidate SD as a false positive based on overall signal power and amplitude analysis and identifying a non-rejected candidate SD as a detected SD.

Abstract: Novel sustained release biodegradable implants and methods of making and of using the same to treat ocular diseases are provided.

Abstract: Described are inventions directed to methods of treating a cardiac dysfunction in a subject that includes administering an amount of probenecid effective to treat a symptom of cardiac dysfunction. The probenecid may be administered in at least one of an injection, orally, or transdermally. The amount of probenecid is sufficient to result in an improved performance on a standardized 6 minute walk test, an improved New York Heart Association (NYHA) classification, a lower diuretic dose requirement, a lower serum BNP levels, a normalization of serum sodium concentrations, and combinations thereof. In an embodiment, probenecid is administered over a period of about 8 hours to about 24 hours. Probenecid may be used for short term treatments, i.e., less than a week, or it may be administered in a long term manner, i.e., over a period of weeks, months, or even years.

Abstract: Systems and methods for an enhanced ultrasound biofeedback therapy for an improved speech remediation treatment for an individual include transmitting a plurality of ultrasound (US) waves toward a tongue of the individual; receiving a plurality of reflected US waves; converting the plurality of reflected US waves into a plurality of US signals to transmit to an ultrasound machine; and generating one or more enhanced images of the tongue at least partially based on the US signals in real-time, the enhanced images including identified Regions of Interest (ROIs) along tongue sub-parts comprising the tongue root, the tongue dorsum, and the tongue blade and respective ROI points identified therein. An interactive visual story is generated and updated in real-time with a tongue-mapping trajectory of the individual on a display based on the enhanced one or more images to determine a successful or unsuccessful sound production.

Abstract: Pharmaceutical compositions of selective EP2 antagonists exemplified by small molecules TG4-155 and TG6-10-1 effective for treating gliomas, and methods for administering the pharmaceutical compositions to treat subjects suffering from disorders characterized by gliomagenesis.

Abstract: Stable, constitutively expressed, chromosomal fluorescent transcriptional fusions in bacterial pathogens and methods of using the same to screen candidate compounds for anti-bacterial efficacy.

Abstract: A high through-put screening method for identifying agents effective for inhibiting biofilm formation and/or killing established biofilm are disclosed. The method includes three tiers, and each tier includes three specific biological process assays. The tier levels are a primary screen, a confirmation screen, and a dose-response screen, and the biological process assays include assays for total bacterial growth, bacterial metabolic activity, and biofilm formation. The series of assays may be run once or more than once at each tier. A library of compounds is subject to tier A and only compounds meeting a primary parameter advance to tier B, and only tier B compounds meeting a confirmation parameter advance to tier C, and only tier C compounds meeting a dose-response parameter are identified as putative agents effective for inhibiting and/or eradicating a biofilm, further wherein the assays are conducted for each compound subject to the respective tier.